Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation

BMC Nephrol. 2021 May 10;22(1):172. doi: 10.1186/s12882-021-02370-6.

Abstract

Background: Patients with kidney disease may have concurrent hypertension and infection. Dihydropyridine calcium-channel blockers (CCB) are the most popular class of antihypertensive drugs used in clinical settings and can be metabolized by cytochrome P450 isoenzyme 3A4 (CYP3A4). Voriconazole is a commonly used antifungal treatment and a CYP3A4-inhibitor. Insufficient attention to drug interactions from the concomitant use of CCB and voriconazole may result in serious adverse reactions.

Case presentation: Here, we report a patient with acute kidney injury on stable anti-neutrophil cytoplasm antibody associated vasculitis who developed hyperkalemia resulting in sinus arrest with junctional escape rhythm attributed to drug interactions of CCB with voriconazole. This is a very rarely reported case and may be an under-recognized complication. After continuous renal replacement therapy and changing the anti-hypertensive drugs, symptoms, and laboratory abnormalities of the patient fully recovered.

Conclusions: This case warns us of severe consequences of drug interactions. Co-prescription of CYP3A4-inhibitors with calcium-channel blockers increases the risk of hypotension and acute kidney injury, which may further induce hyperkalemia and arrhythmia.

Keywords: Acute kidney injury; Arrhythmia; Calcium‐channel blockers; Drug interaction; Hyperkalemia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / therapy
  • Aged
  • Antibodies, Antineutrophil Cytoplasmic
  • Antifungal Agents / adverse effects
  • Antihypertensive Agents / adverse effects*
  • Calcium Channel Blockers / adverse effects*
  • Cytochrome P-450 CYP3A Inhibitors / adverse effects*
  • Diagnosis, Differential
  • Drug Interactions
  • Female
  • Humans
  • Hyperkalemia / chemically induced*
  • Hyperkalemia / drug therapy
  • Renal Replacement Therapy
  • Sinus Arrest, Cardiac / chemically induced*
  • Sinus Arrest, Cardiac / drug therapy
  • Vasculitis / complications
  • Vasculitis / diagnosis
  • Vasculitis / drug therapy
  • Voriconazole / adverse effects*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antifungal Agents
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Cytochrome P-450 CYP3A Inhibitors
  • Voriconazole